Scandion Oncology strengthens its Clinical Advisory Board with three new members
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the company has strengthened its Clinical Advisory Board with three international highly experienced Key Opinion Leaders in oncology.
With Professor Richard Schilsky already on board since April 2021, the Clinical Advisory Board now consists of four members. The three new members are Professor Josep Tabernero, MD, PhD; Professor Eric Van Cutsem, MD, PhD; and Professor Thomas Seufferlein, MD.
“I am thrilled and humbled that we have been able to expand our stellar clinical advisory board with this team of world leading key opinion leaders. It is a recognition of the importance the cancer community sees in the development of SCO-101, and it supports Scandion Oncology’s important mission of improving lives for patients with drug resistant cancer,” said Bo Rode Hansen, President & CEO of Scandion Oncology.
Short resumes of the new members:
Josep Tabernero, MD, PhD: Professor and Head of the Medical Oncology Department and Director of the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. He is a member of the Executive Board of the European Society for Medical Oncology (ESMO) having served as ESMO President in 2018 – 2019. He has been appointed as member of several Educational and Scientific Committees of ESMO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastro-intestinal, and ESMO-GI/WCGIC meetings. Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery and Clinical Cancer Research. He has (co) authored approximately 450 peer-reviewed papers. He is a highly respected leader in the field of clinical oncology and specializes in new drug development and treatment of gastrointestinal cancers.
Eric Van Cutsem, MD, PhD: Professor and Division Head of Digestive Oncology at University of Leuven and University Hospitals Gasthuisberg, Leuven, Belgium and is the president of the Belgian Foundation against Cancer. Dr. Van Cutsem has received several awards, amongst others the European Society for Medical Oncology (ESMO) Award in 2019 and the European Awards in Medicine for Cancer Research. He co-founded ESMO GI/World Congress on Gastrointestinal Cancer, and is Chair of the meeting in Barcelona, Spain. He serves/served on the board or key committee of ESMO (executive board and several committees), ASCO (program committee and international affairs committee), EORTC (executive board and chair GI Cancer group), ENET (advisory board), ECCO (program committee), ESDO (president), UEG (Scientific Committee, public affairs committee), ESO (scientific committee), BGDO (Belgian Group Digestive Oncology), FAPA (Familial Adenomatous Polyposis Association) and of the patient advocacy groups, Europacolon and Digestive Cancers Europe (co-founder and executive board). He was chairman of the governmental colon cancer prevention task force in Flanders, Belgium. He has published > 630 peer-reviewed papers on pubmed leading to an H-factor of 135 and to more than 88.000 citations.
Thomas Seufferlein, MD: Professor and Medical Director at the Department of Internal Medicine I and Deputy Director Comprehensive Cancer Center at Ulm University Hospital in Germany. Dr. Seufferlein is a member of several German and European scientific groups and organizations. He is currently President of the German Cancer Society (DKG), chairman of the committee for cancer prevention of the German Cancer Aid (DKH), the steering committee of the German Program for Oncological Guidelines of DKG, DKH and AWMF, and of the certification commission of the DKG-certified colorectal cancer centers. He has published >310 in peer reviewed journals and is since 2010 Editor in Chief of the German Journal of Gastroenterology.
For further information regarding Scandion Oncology, please contact:
Bo Rode Hansen, President & CEO
Phone: +45 3810 2017
This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on September 7, 2021, at 8:30 CET
Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at firstname.lastname@example.org or +46 (0) 40 200 250.